期刊
CHINESE CLINICAL ONCOLOGY
卷 7, 期 2, 页码 -出版社
AME PUBL CO
DOI: 10.21037/cco.2018.04.04
关键词
Cancer; oncolytic; virus; antitumor immunity
类别
资金
- NCI NIH HHS [R01 CA175795, R01 CA207240, P50 CA186781, P30 CA015083] Funding Source: Medline
This review discusses current clinical advancements in oncolytic viral therapy, with a focus on the viral platforms approved for clinical use and highlights the benefits each platform provides. Three oncolytic viruses (OVs), an echovirus, an adenovirus, and a herpes simplex-1 virus, have passed governmental regulatory approval in Latvia, China, and the USA and EU. Numerous other recombinant viruses from diverse families are in clinical testing in cancer patients and we highlight the design features of selected examples, including adenovirus, herpes simplex virus, measles virus, retrovirus, reovirus, vaccinia virus, vesicular stomatitis virus. Lastly, we provide thoughts on the path forward for this rapidly expanding field especially in combination with immune modulating drugs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据